Previous 10 | Next 10 |
BioLineRx (BLRX) +62% on positive top-line results from GENESIS phase 3 trial.Cocrystal Pharma (COCP) +40%.Huttig Building Products, Inc. (HBP) +26% on Q1 results.Vaxart (VXRT) +20% as its oral COVID-19 vaccine shows potential to offer promising solution against variants.Precip...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning and welcome to another busy day of trading on the stock market. We’re keeping up with the latest trading trends as we check out the biggest pre-market stock movers for Tuesday morning. Source: Eric U...
Cocrystal Pharma (COCP) announces progress in developing broad-spectrum antiviral drug candidates that COVID-19. In December 2020, Cocrystal selected CDI-45205 as its lead coronavirus development candidate under an exclusive license agreement with Kansas State University Research Foundation. ...
Brooklyn ImmunoTherapeutics (BTX) +38%.Regional Health Properties (RHE) +21%.Gaucho Group Holdings (VINO) +15%.Ashford Hospitality Trust (AHT) +15%.Ocugen (OCGN) +13% as COVAXIN demonstrated potential effectiveness against the Brazil variant of SARS-CoV-2, B.1.128.2.DAVIDsTEA (DTEA) +10%...
BOTHELL, Wash., May 03, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machiner...
The FDA approval process for vaccines, therapeutics, and other pharmaceuticals was on the nightly news through late 2020. Investors and non-investors alike developed some understanding of that FDA timeline. Medical device clearance is less understood yet critical for investors looking to benef...
Gainers: Bonso Electronics International (BNSO) +36%.SOS (SOS) +29%.Ouster (OUST) +29%.ION Geophysical (IO) +22%.Odonate Therapeutics (ODT) +20%.Titan Medical (TMDI) +16%.Cocrystal Pharma (COCP) +15%.Ocugen (OCGN) +15%.Pintec Technology (PT) +13%.Frequency Therapeutics (FREQ) +...
Cocrystal Pharma (COCP): FY GAAP EPS of -$0.17 beats by $0.03.Revenue of $2M (-69.5% Y/Y) misses by $0.08M.Shares +0.63% PM.Press Release For further details see: Cocrystal Pharma EPS beats by $0.03, misses on revenue
Outlines 2021 product pipeline milestones for COVID-19, influenza A and norovirus antiviral programs Ends 2020 with cash exceeding $33 million and a clean capital structure BOTHELL, Wash., March 17, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), ...
Cocrystal Pharma (COCP) announces an extension of its drug discovery collaboration with HitGen and computer software company InterX with the agreement now continuing through August 2023.Through the collaboration, Cocrystal, HitGen and InterX scientists are applying HitGenȁ...
News, Short Squeeze, Breakout and More Instantly...
Cocrystal Pharma Inc. Company Name:
COCP Stock Symbol:
NASDAQ Market:
Cocrystal Pharma Inc. Website:
FDA feedback following the Company’s submission of a Pre-IND briefing package improves clarity on regulatory requirements for Phase 2b influenza A clinical trial with oral CC-42344, a broad-spectrum PB2 inhibitor Topline data expected in 2024 from Phase 2a influenza A human challen...
Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash., March 19, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has received Pre-Investigational New D...
LOS ANGELES, CA / ACCESSWIRE / March 5, 2024 / Planet MicroCap today published a new Video Interview with Jim Martin, Co-CEO and CFO, from Cocrystal Pharma, Inc. (NASDAQ:COCP), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replicat...